TKAI - Tokai Pharmaceuticals Mon 27'th Feb 2017
Stock analysis for Mon 27'th Feb 2017 (Updated daily)
Sell candidate since 2017-02-13
Tokai Pharmaceuticals Stock Analysis
Tokai Pharmaceuticals gained 2.46% in the last trading day, rising from USD 0.85 to USD 0.88. The price has fallen in 7 of the last 10 days and is down by -6.81% for this period. Volume fell in the last day by -18 807 shares and ,in total, 98 145 shares bought and sold for approximately USD 86 368. You should note that falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.
Tokai Pharmaceuticals lies in the middle of a very wide and strong falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -16.6% during the next 3 months and, with 90% probability hold a price between USD 0.68 and USD 0.88 at the end of this period.
A buy signal was issued from a pivot bottom point on Friday February 24, 2017, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Tokai Pharmaceuticals holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at USD 0.88 and USD 0.95. A break-up above any of these levels will issue buy signals. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may not be. The very low volume increases the risk and reduces the other technical signals issued.
Relative Strength Index (RSI)
RSI14 is 34 and the stock is currently not being overbought or oversold
Support & Resistance
Tokai Pharmaceuticals finds support from accumulated volume at USD 0.86, USD 0.85. On the upside the stock meets some resistance from accumulated volume at USD 1.04, USD 1.03 and USD 1.05.
In general the stock tends to have controlled movements, but the low liquidity has increased the risk substantially.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Tokai Pharmaceuticals holds several negative signals and is within a very wide and strong falling trend, so we believe it will still perform weak in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Hold/Accumulate to a Sell Candidate.